BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine
On the premise of ensuring the safety and effectiveness of the vaccine, we actively support the marketing of the vaccine in China.
- On the premise of ensuring the safety and effectiveness of the vaccine, we actively support the marketing of the vaccine in China.
- The BNT162b2 mRNA vaccine is a successful model of international R&D collaboration, Wu Yifang, Chairman and CEO of Fosun Pharma said.
- We are pleased to reach the supply agreement with BioNTech, which is an important step in Fosun Pharma and BioNTech's efforts to achieve vaccine accessibility and affordability in China.
- Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) is a leading healthcare group in China.